Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials

Background: Based on the experience with selective cyclooxygenase (COX)-2 inhibitors, including rofecoxib, valdecoxib, and celecoxib, it was anticipated that etoricoxib, a new selective COX-2 inhibitor, would display mechanism-based, dose-dependent renal adverse effects (AEs) similar to those observ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2004, Vol.26 (1), p.70-83
Hauptverfasser:	Curtis, Sean P., Ng, Jennifer, Yu, Qinfen, Shingo, Sumiko, Bergman, Gina, McCormick, Calogera L., Reicin, Alise S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anti-inflammatory agents Anti-Inflammatory Agents, Non-Steroidal - adverse effects Back pain Biological and medical sciences Biosynthesis Clinical trials Clinical Trials, Phase III as Topic Cyclooxygenase Inhibitors - administration & dosage Cyclooxygenase Inhibitors - adverse effects Dose-Response Relationship, Drug Drug dosages etoricoxib Female Health economics Humans Hypertension Kidney Diseases - chemically induced Male Medical sciences Middle Aged Nonsteroidal anti-inflammatory drugs Osteoarthritis Pharmacology. Drug treatments Phase III studies Pyridines - administration & dosage Pyridines - adverse effects renal safety Rheumatoid arthritis Rheumatology selective cyclooxygenease-2 inhibitors Sulfones - administration & dosage Sulfones - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!